Christine J Weegink
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Christine J Weegink has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
H.W. Reesink
5 shared publications- Hans L. Zaaijer
Department of Blood-Borne Infections, Donor Medicine Research, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands
3 shared publications - Marcel Beld
Section of Clinical Virology, Department of Medical Microbiology
3 shared publications - Annikki de Niet
Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands
2 shared publications H.L.A. Janssen
2 shared publicationsM.G.W. Dijkgraaf
2 shared publications
Latest Publications
- 1 August 2012
- Vol. 70 (6) , 261-6
Chronic hepatitis E after solid organ transplantation.
Large outbreaks of acute hepatitis E, caused by hepatitis E virus (HEV) genotypes 1 and 2, are known from developing countries with suboptimal sanitation infrastructure. An increasing incidence of HEV infections is being reported in industrialised countries, caused mainly by HEV genotypes 3 and 4, which are often found among pigs. Recent evidence suggests that in immunocompromised patients about 50% of the cases of acute hepatitis E evolve to chronic hepatitis with rapid progression to cirrhosis. Thus, HEV should be considered a cause of chronic hepatitis in immunocompromised patients, such as solid organ transplant recipients. Because an antibody response to HEV may be absent in these patients, an HEV RNA test should be carried out when serum liver tests are elevated over months. In small case series, ribavirin has been shown to represent a promising treatment option for chronic HEV infection. To increase the awareness for HEV infection in immunocompromised patients, a representative case report of an HEV-infected renal transplant recipient with chronic hepatitis E, successfully treated with ribavirin, is presented. Studies are required to determine the optimal duration of ribavirin therapy and to assess outcome for solid organ transplant recipients with chronic HEV infection.
- 1 August 2012
- Vol. 70 (6) , 261-6
Chronic hepatitis E after solid organ transplantation.
Large outbreaks of acute hepatitis E, caused by hepatitis E virus (HEV) genotypes 1 and 2, are known from developing countries with suboptimal sanitation infrastructure. An increasing incidence of HEV infections is being reported in industrialised countries, caused mainly by HEV genotypes 3 and 4, which are often found among pigs. Recent evidence suggests that in immunocompromised patients about 50% of the cases of acute hepatitis E evolve to chronic hepatitis with rapid progression to cirrhosis. Thus, HEV should be considered a cause of chronic hepatitis in immunocompromised patients, such as solid organ transplant recipients. Because an antibody response to HEV may be absent in these patients, an HEV RNA test should be carried out when serum liver tests are elevated over months. In small case series, ribavirin has been shown to represent a promising treatment option for chronic HEV infection. To increase the awareness for HEV infection in immunocompromised patients, a representative case report of an HEV-infected renal transplant recipient with chronic hepatitis E, successfully treated with ribavirin, is presented. Studies are required to determine the optimal duration of ribavirin therapy and to assess outcome for solid organ transplant recipients with chronic HEV infection.
- 31 December 2006
- Published by Elsevier in Journal of Clinical Virology
- Vol. 36, S139
P.249 Recurrence or persistence of HCV RNA detectable only by TMA during antiviral therapy
- 31 December 2006
- Published by Elsevier in Journal of Clinical Virology
- Vol. 36, S139
P.249 Recurrence or persistence of HCV RNA detectable only by TMA during antiviral therapy
- 1 December 2003
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 15 (12) , 1367-1369
A physician with a positive hepatitis C virus RNA test after a needlestick injury
Needlestick accidents continue to be a hazard for healthcare workers. We report the development of acute hepatitis C infection in a physician after needlestick injury. Hepatitis C virus (HCV)-RNA, seroconversion and a raised plasma alanine aminotransferase (ALAT) level were found in plasma three months after the accident. Treatment with interferon alfa and ribavirin was started. While the physician was on treatment, HCV-RNA test results from plasma taken the day treatment was started became available. HCV-RNA was undetectable by quantitative bDNA assay, undetectable by qualitative polymerase chain reaction (PCR) and undetectable by transcription mediated amplification (TMA). A dilemma arose at this point: should the patient stop the treatment or continue the planned therapy? The physician decided to continue a 24-week course of treatment. Six months after the end of treatment, the physician was still HCV-RNA-negative and with a normal plasma ALAT level. The rationale of the decision to continue therapy is discussed. This information may be useful for clinicians confronted with a similar dilemma.
- 1 December 2003
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 15 (12) , 1367-1369
A physician with a positive hepatitis C virus RNA test after a needlestick injury
Needlestick accidents continue to be a hazard for healthcare workers. We report the development of acute hepatitis C infection in a physician after needlestick injury. Hepatitis C virus (HCV)-RNA, seroconversion and a raised plasma alanine aminotransferase (ALAT) level were found in plasma three months after the accident. Treatment with interferon alfa and ribavirin was started. While the physician was on treatment, HCV-RNA test results from plasma taken the day treatment was started became available. HCV-RNA was undetectable by quantitative bDNA assay, undetectable by qualitative polymerase chain reaction (PCR) and undetectable by transcription mediated amplification (TMA). A dilemma arose at this point: should the patient stop the treatment or continue the planned therapy? The physician decided to continue a 24-week course of treatment. Six months after the end of treatment, the physician was still HCV-RNA-negative and with a normal plasma ALAT level. The rationale of the decision to continue therapy is discussed. This information may be useful for clinicians confronted with a similar dilemma.
- 28 April 2003
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 10 (3) , 174-182
Chronic hepatitis C patients with a post‐treatment virological relapse re‐treated with an induction dose of 18 MU interferon‐α in combination with ribavirin and amantadine: a two‐arm randomized pilot study
Summary. Thirty‐seven chronic hepatitis C patients with virological relapse (VR) after previous interferon‐α (IFN) or IFN/ribavirin (Riba) therapy, were re‐treated. Patients were randomized for either IFN/Riba and amantadine (Ama) including a 2‐week initial high IFN induction course (18 MU IFN daily) (group A) or the same 2‐week IFN induction course combined with Riba/Ama, followed by Riba/Ama without IFN (group B). Treatment duration for both groups was 24 weeks with a 24‐week follow‐up thereafter. The inclusion in group B was prematurely stopped because all patients (n = 10) relapsed within 2 weeks after stopping IFN. Therefore, all subsequent patients were included in group A (n = 27). In group A, 44% achieved a sustained virological response (SVR) and 29% of the patients with an end‐of‐treatment virological response had a VR again. Of all pretreatment characteristics, only genotype non‐1 patients had a significantly higher chance of achieving SVR (P < 0.001). Of the characteristics during treatment only a negative hepatitis C virus (HCV)‐RNA test result in transcription‐mediated amplification (TMA) at week 6 had a high predictive value for SVR, 80% in all patients and 92% in genotype non‐1 patients. In conclusion, hepatitis C patients with a VR to previous antiviral treatment can be succesfully re‐treated with IFN induction combined with Riba/Ama for only 6 months, when they have genotype non‐1 and a negative HCV‐RNA test result in TMA 6 weeks after the start of therapy. Riba/Ama combination therapy without IFN does not prevent VR after 2 weeks high IFN induction.
- 28 April 2003
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 10 (3) , 174-182
Chronic hepatitis C patients with a post‐treatment virological relapse re‐treated with an induction dose of 18 MU interferon‐α in combination with ribavirin and amantadine: a two‐arm randomized pilot study
Summary. Thirty‐seven chronic hepatitis C patients with virological relapse (VR) after previous interferon‐α (IFN) or IFN/ribavirin (Riba) therapy, were re‐treated. Patients were randomized for either IFN/Riba and amantadine (Ama) including a 2‐week initial high IFN induction course (18 MU IFN daily) (group A) or the same 2‐week IFN induction course combined with Riba/Ama, followed by Riba/Ama without IFN (group B). Treatment duration for both groups was 24 weeks with a 24‐week follow‐up thereafter. The inclusion in group B was prematurely stopped because all patients (n = 10) relapsed within 2 weeks after stopping IFN. Therefore, all subsequent patients were included in group A (n = 27). In group A, 44% achieved a sustained virological response (SVR) and 29% of the patients with an end‐of‐treatment virological response had a VR again. Of all pretreatment characteristics, only genotype non‐1 patients had a significantly higher chance of achieving SVR (P < 0.001). Of the characteristics during treatment only a negative hepatitis C virus (HCV)‐RNA test result in transcription‐mediated amplification (TMA) at week 6 had a high predictive value for SVR, 80% in all patients and 92% in genotype non‐1 patients. In conclusion, hepatitis C patients with a VR to previous antiviral treatment can be succesfully re‐treated with IFN induction combined with Riba/Ama for only 6 months, when they have genotype non‐1 and a negative HCV‐RNA test result in TMA 6 weeks after the start of therapy. Riba/Ama combination therapy without IFN does not prevent VR after 2 weeks high IFN induction.
- 1 January 2001
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 36 (1) , 97-104
Sustained Virological Response in Chronic Hepatitis C Patients after a 6- and a 36-Month Interferon-α2b Treatment Schedule. A Multicenter, Randomized, Controlled Study
Search and browse 5 million articles across 13,000 publications from over 250 publishers by publication, subject, publisher, author or keyword.
- 1 January 2001
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 36 (1) , 97-104
Sustained Virological Response in Chronic Hepatitis C Patients after a 6- and a 36-Month Interferon-α2b Treatment Schedule. A Multicenter, Randomized, Controlled Study
Search and browse 5 million articles across 13,000 publications from over 250 publishers by publication, subject, publisher, author or keyword.